Nello Mainolfi, Kymera Therapeutics CEO

Kymera dou­bles down on pro­tein de­graders for im­munol­o­gy, chas­ing Dupix­ent and So­tyk­tu

Look­ing to fur­ther ex­pand the reach of pro­tein de­graders be­yond can­cer, Kymera Ther­a­peu­tics re­vealed two new pro­grams Thurs­day morn­ing that it hopes will com­pete with some of the hottest im­munol­o­gy drugs on the mar­ket.

One of Kymera’s com­pounds mim­ics Dupix­ent, an in­jec­tion that Re­gen­eron and Sanofi mar­ket for sev­er­al con­di­tions that is on track to gen­er­ate more than $10 bil­lion in an­nu­al sales. Kymera’s sec­ond new drug goes af­ter the same tar­get as So­tyk­tu, a pill sold by Bris­tol My­ers Squibb for plaque pso­ri­a­sis that’s be­ing test­ed for a bevy of im­mune-re­lat­ed con­di­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.